liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Health-care costs of losartan and candesartan in the primary treatment of hypertension
AstraZeneca.
Oslo University Hospital.
AstraZeneca.
Oslo University Hospital.
Show others and affiliations
2011 (English)In: JOURNAL OF HUMAN HYPERTENSION, ISSN 0950-9240, Vol. 25, no 2, 130-136 p.Article in journal (Refereed) Published
Abstract [en]

A recent study of two widely used angiotensin receptor blockers reported a reduced risk of cardiovascular events (-14.4%) when using candesartan compared with losartan in the primary treatment of hypertension. In addition to clinical benefits, costs associated with treatment strategies must be considered when allocating scarce health-care resources. The aim of this study was to assess resource use and costs of losartan and candesartan in hypertensive patients. Resource use (drugs, outpatient contacts, hospitalizations and laboratory tests) associated with losartan and candesartan treatment was estimated in 14 100 patients in a real-life clinical setting. We electronically extracted patient data from primary care records and mandatory Swedish national registers for death and hospitalization. Patients treated with losartan had more outpatient contacts (+15.6%), laboratory tests (+13.8%) and hospitalizations (+13.8%) compared with the candesartan group. During a maximum observation time of 9 years, the mean total costs per patient were 10 369 Swedish kronor (95% confidence interval: 3109-17 629) higher in the losartan group. In conclusion, prescribing candesartan for the primary treatment of hypertension results in lower long-term health-care costs compared with losartan.

Place, publisher, year, edition, pages
Nature Publishing Group , 2011. Vol. 25, no 2, 130-136 p.
Keyword [en]
cardiovascular disease, cost analysis, economic evaluation, blood pressure
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:liu:diva-65562DOI: 10.1038/jhh.2010.36ISI: 000286179500009OAI: oai:DiVA.org:liu-65562DiVA: diva2:396790
Available from: 2011-02-11 Created: 2011-02-11 Last updated: 2014-09-23

Open Access in DiVA

fulltext(395 kB)145 downloads
File information
File name FULLTEXT01.pdfFile size 395 kBChecksum SHA-512
ba1358dd733be5bc62eb5949dd7d654d0c0e46fa4914888ca55ca82f54a2c0317d0dbc7dc0357c7622568e6cc9d867839f6e2d159fb1053837f1935c7c9406d4
Type fulltextMimetype application/pdf

Other links

Publisher's full text

Authority records BETA

Levin, Lars-Åke

Search in DiVA

By author/editor
Levin, Lars-Åke
By organisation
Health Technology Assessment and Health EconomicsFaculty of Health Sciences
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 145 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 99 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf